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Abstract: Facilitative sugar transporters (GLUTs) are the primary method of sugar uptake in all
mammalian cells. There are 14 different types of those transmembrane proteins, but they transport
only a handful of substrates, mainly glucose and fructose. This overlap and redundancy contradict the
natural tendency of cells to conserve energy and resources, and has led researchers to hypothesize that
different GLUTs partake in more metabolic roles than just sugar transport into cells. Understanding
those roles will lead to better therapeutics for a wide variety of diseases and disorders. In this review
we highlight recent discoveries of the role GLUTs play in different diseases and disease treatments.
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1. Overview of GLUTs
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GLUTs are passive membrane transporters that pass glucose and other similar substrates like fructose, mannose, ascorbate, and urate ions. They have been classified into
three classes based on their sequence similarity and substrate affinity. Table 1 [1] shows an
overview of the 14 members of the GLUT family, their currently known substrates, and
their expression sites. The Class I GLUTs (1–4 and 14) facilitate the uptake of glucose and
other hexoses, but not fructose. The Class II GLUTs (5, 7, 9 and 11) are fructose transporters,
and Class III GLUTs (6, 8, 10, 12, and 13 (HMIT1)) are structurally atypical members. The
affinity of each transporter for glucose ranges from 0.2 to 17 mM.
Only GLUTs 1–5 have been studied in depth, and relatively little is known about
the other GLUTs. This section provides an overview of the transport efficiencies, tissue
expression, and links to different disorders of all 14 GLUTs.
1.1. Class I
GLUT1 was the first GLUT to be identified. It is ubiquitously found in all tissues of the
body. GLUT1 also transports glucose through the blood-brain barrier [2,3], and is expressed
in other barrier structures in the brain [4]. Its main substrate is glucose (Km = 3 mM [5]),
and other known substrates include galactose, mannose, and glucosamine [6]. GLUT1 is
overexpressed in many different types of cancers including brain [7], breast [8], cervix [9],
colon [10], kidney [11], lung [12], ovary [13], prostate [14], skin [15], and thyroid [16].
Cancers that express more GLUT1 have been shown to be more aggressive and invasive [17].
Due to its widespread prevalence, many different therapies have attempted to target it, but
the same widespread prevalence makes it difficult to achieve specificity.
GLUT2 has a sequence similarity of 55% to GLUT1. It is primarily expressed in
the liver, kidney, insulin-secreting pancreatic beta cells, and absorptive epithelial cells
of the intestinal mucosa. Its main function is regulating the uptake of glucose in the
gastrointestinal tract [18,19]. GLUT2 partakes in glucose uptake (Km = 17 mM), but its
main substrate is glucosamine (Km = 0.8 mM) [6]. It also transports fructose, galactose,
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and mannose (Km = 76 mM, 92 mM and 125 mM, respectively) [20–22]. Since it plays a
role in carbohydrate uptake in the intestines, it has become a target of interest
2 of 18
for diabetes prevention and treatment by inhibiting glucose absorption in the intestine and
thereby lowering blood glucose levels [23].
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Table 1. classification, expression, and substrate preference of the 14 known GLUTs.
Table 1. Classification, expression, and substrate preference of the 14 known GLUTs.

GLUT1
GLUT2
GLUT3
GLUT4
GLUT14
GLUT5
GLUT7
GLUT9
GLUT11
GLUT6
GLUT8
GLUT10
GLUT12

Expression Tissues
Main Substrates
Erythrocytes, blood-tissue barriers
Glucose, 2-DG
Liver, pancreas, small intestine
Glucose, Glucosamine
Neurons
Glucose, 2-DG
Adipocytes, muscle, heart
Glucose, Glucosamine
Testis
Unknown
Testis, intestine, muscle
Fructose
Testis, intestine, prostate
Fructose, glucose
Liver, kidney
Urate
Pancreas, kidney, placenta, muscle
Fructose, glucose
Brain, spleen, leukocytes
Glucose
Testis, neurons, adipocytes
Glucose, trehalose
Liver, pancreas
2-DG
Heart, prostate
Glucose
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Class III
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GLUT4 is the dominant glucose transporter in striated muscle and adipose tissues,
and is the second most abundant transporter in cardiovascular tissue [32]. Its main substrate is glucose (Km ≈ 5 mM [33]) and it also transports mannose, galactose, dehydroascorbic acid, and glucosamine [34]. Unlike other glucose transporters, GLUT4 is regulated by
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only substrate is fructose (Ki = 5–15 mM [40]). It is primarily expressed in the small intestine [41] and has been strongly linked to cancer development, progression and metastasis,
making it an attractive target for cancer therapeutics [42]. This, along with its unique
substrate specificity, prompted several structural activity relationship (SAR) studies into its
H-bonding requirements for fructose uptake in order to design GLUT5-specific probes as
cancer diagnostic tools [43–45]. Furthermore, the heightened consumption of fructose in
cancers lead to the development of GLUT5-specific inhibitors of fructose uptake [42,46].
GLUT7 is primarily expressed in the small intestine and colon, although its mRNA
has been detected in the prostate and testis. It has a sequence identity of 44% to GLUT5 [47].
GLUTs 9 and 11 share 58.1% and 41.7% sequence identity with GLUT5, respectively [40,48].
All three transporters have high affinities (<0.5 mM) for both glucose and fructose [47,49].
GLUT9 is mainly expressed in the liver and kidney [49], and GLUT11 has been found in
various organs, including the heart, skeletal muscle, kidney and pancreas [50]. GLUTs 7 and
9 are also expressed in the apical membrane of the small intestine and colon. The abundance
of GLUTs 7 and 9 in the small intestine changes according to dietary carbohydrate intake.
However, the distribution of transporters along the small intestine does not entirely match
the availability of glucose and fructose, which might indicate the presence of another
substrate for those transporters that has yet to be identified.
1.3. Class III
The members of this class share a limited sequence homology with class I (~25%
identity) and are considered structurally atypical [51]. GLUT10 has a 35% similarity to
GLUT2 and it can also transport glucose (Km = 2 mM). GLUT12 has a number of similar
features to GLUT4, but a much higher affinity for glucose (Km = 0.3 mM) [52].
GLUT8 is predominantly expressed in the testes [53] and is thought to play a major
role in providing glucose to mature spermatozoa, in addition to being able to transport
fructose [54]. It is also expressed in a number of other tissues such as the liver, spleen,
brown adipose and blastocysts, albeit in significantly lower quantities [55]. The expression of GLUT8 was suggested to be regulated by insulin in a similar manner to GLUT4.
However, this claim has been disputed [56,57]. There is some evidence that glucose itself
may influence the location and expression of GLUT8, as glucose induces GLUT8 translocation from an intracellular compartment to the endocyclic reticulum in rat hippocampal
cells [58]. GLUT8 knock-out mice reportedly displayed normal embryonic and postnatal
development and glucose homeostasis, but had mild defects in hippocampal neurogenesis
and cardiac function.
GLUT12, like GLUT8, is also able to transport both glucose and fructose. Insulinregulated expression has also been suggested for GLUT12, as it is predominantly expressed
in the insulin-sensitive skeletal muscle, heart and fat tissues [52]. GLUT12 was originally
cloned from the human breast cancer cell line, MCF7, and its expression was found to
be stronger in ductal cell carcinoma than in benign ducts of breast cancer tissues [59],
indicating a possible role in glucose uptake in breast cancer tissue.
HMIT, formerly known as GLUT13, is an H+ /myo-inositol cotransporter and is the
last of the GLUTs. Unlike the other 13 transporters, HMIT does not transport either glucose
or fructose. Its only substrate is myo-inositol (Km ≈ 100 mM), and this uptake is pHdependent [60]. HMIT is largely expressed in the brain, particularly in neuron intracellular
vesicles, and its transition to the cell surface can be triggered by cell depolarization.
2. Carbohydrate Uptake and Metabolic Disorders
Increased carbohydrate consumption is implicated in a variety of diseases, including obesity, type 2 diabetes [61], nonalcoholic fatty liver disease [62], gout, sclerosis, and
Alzheimer’s disease [63]. High glucose or fructose uptake are associated with increased
cancer growth and metastasis [64,65]. Therefore, the changes in GLUT expression and
composition occur to meet the additional energy demands of uncontrolled cell growth and
division. For example, the expression of the normally ubiquitous GLUT1becomes unpre-
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dictable, with some cancers overexpressing this transporter and others downregulating
it [66]. Thus, GLUT1 has been found to be overexpressed in the squamous cell carcinoma of
lung cancer, but not in normal or adenocarcinoma lung cells [67]. Likewise, GLUT3 gains
expression in various types of cancer, while normally being only expressed in the brain [68].
The overexpression of GLUT5 and GLUT12 bas been observed in both the early-stage
breast carcinoma cell line MCF7, and the late-stage cell line MDA-MB-231 [69,70]. GLUT5
is similarly overexpressed in pancreatic, ovarian, and lung cancers and leukemia [42,71].
Despite this, the relationship between sugar consumption and the development of
cancer is not clear cut. While it was shown that a diet high in fats and sugars contributes
to the reoccurrence of stage III colon cancer, it did not have any impact on the overall
risk of colon or any other type of cancer, or it showed an increased risk in only a narrow
population. On the other hand, high sugar consumption is strongly linked to obesity,
and there is an established link between obesity and cancer [72]. Increased circulating
insulin and insulin-like growth factor levels also have been linked with cancer progression,
suggesting that both obesity and insulin resistance might promote cancer development by
activating cell growth signaling pathways [73,74].
Alterations in sugar uptake in metabolically-compromised cells led to the development of sugar transport-targeting therapeutic approaches. Cell starvation in sugars was
found to diminish the viability of cancer cells [75] and improve therapeutic outcomes [76].
The approach relied on the resilience of normal cells to the nutrient deprivation, while
cancer cells remained vulnerable [77]. The induced stress in cancer cells was observed to
play a role of a sensitizer and enhance their response to chemotherapy agents [77]. Such a
cancer sensitization strategy promoted the development of ketogenic diets that allow for
the limiting of sugar consumption [78]. Along with the development of dietary approaches,
direct methods to modulate sugar uptake in cells have been developed. This approach
relies on a direct inhibition of sugar uptake in cells using GLUT inhibitors. Several comprehensive reviews have summarized the natural or synthetic GLUT inhibitors [1,79,80].
Downregulating the expression of selected GLUTs has also been proposed as a potential
therapeutic strategy. Over the last several years, significant advances have been made
towards diversifying the library of inhibitors in addition to streamlining their specificity
as well as broadening the assessment of GLUT inhibition outcomes. In addition, new
connections between GLUTs and disease have recently been identified, which could lead to
new additional diagnostic and therapeutic approaches. An update of recent advances for
several different diseases (in alphabetical order) follows below.
3. Recent Examples of GLUT Associated Diseases
3.1. Arterial Tortuosity Syndrome
ATS is a connective tissue disorder that causes tortuosity and aneurysm formation
in the major arteries. It is a rare genetic disorder caused by mutations in the GLUT10
gene that cause it to stop functioning. Researchers in the past failed to induce ATS in mice
using GLUT10 knockout, since mice are able to synthesize dehydroascorbic acid, one of
the substrates of GLUT10. By contrast, humans cannot synthesize dehydroascorbic acid,
so the authors did a double knockout of GLUT10 and L-gulonolactone oxidase, a critical
enzyme for ascorbic acid synthesis in mice. The vasculature of double knockout, single
knockout, and wild type mice was measured by ultrasound. For double knockout mice
of both genders of mice across all measured blood vessels, the diameter of the vessels
was 1 mm smaller on average. Those deviations were not enough to be considered as
a reproduction of the major hallmarks of ATS in humans. However, an in vitro culture
showed that DKO mice had weakened extracellular matrix structures, with fewer and
thinner collagen links compared to the WT mice.
GLUT10 knockout has been previously associated with impaired mitochondrial function, and this model does demonstrate that when comparing the oxygen consumption rate
of the DKO mice and WT mice, the basal consumption of DKO mice was about 70 pmol/min
lower than the WT, while the maximum rate was lower by as much as 350 pmol/min, a
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difference of more than three-fold [81]. This work demonstrated the importance of GLUT10
in dehydroascorbic acid transport and mitochondrial function; the underlying mechanism
of the latter remains unknown. Further research is needed to develop a better model for
ATS as well as to understand the link between GLUT10 and mitochondrial function.
3.2. Cancer
3.2.1. Breast Cancer
Triple-negative breast cancer (TNBC) is infamous for its aggression, poor prognosis,
and limited treatment options. How much TNBC relies on glycolysis had been largely
unknown until recently, when it was shown that GLUT12 plays a key role in TNBC growth
and was associated with worse clinical outcomes for TNBC patients. Analyzing 193 samples
of TNBC tumors and 864 non-TNBC tumors, the former had an average of 27.5% higher
GLUT12 expression (p = 2.7 × 10−36 ). In addition, a sample of 78 TNBC patients with high
GLUT12 expression were able to survive for up to 100 months, which is half as long as 107
patients with low GLUT12 expression (p = 0.041). This data highlighted the need for TNBC
therapies that target GLUT12.
A microRNA (miRNA) sequence called let-7a-5p was identified in silico to suppress
GLUT12 expression. This was confirmed in-vitro using HEK293T cells, which when given
let-7a-5p showed only one third of the GLUT12 expression of the negative control. Next, it
was found that let-7a-5p reduced the proliferation of MDA-MB-231 and MDA-MB-468 cells
by half after four days compared to the negative control. Restoring GLUT12 expression
resulted in near identical proliferation to the negative control. Finally, nude mice (n = 6) with
grafted MDA-MB-231 cells expressing firefly luciferase were imaged at 30 days. The mice
that received let-7a-5p had visibly lower florescence compared to mice given scrambled
miRNA. Dissecting their lungs showed they had an average of 10 tumor nodules compared
to 40 for the control [82]. This study demonstrates the importance of GLUT12 and the role
it plays in TNBC, and how it offers a new promising therapeutic pathway.
Another study looked at RIP140, a protein that, among many other functions, suppresses cell division and cellular metabolism, and cancer cells are often deficient in that
protein. Transformed MEF cells with RIP140 knockout had a tumor volume of 2500 mm3 on
average after 40 days in mice, while the wild type volume was only 500 mm3 , a difference
of fivefold. The tumor weights were 1.3 g and 0.4 g, respectively.
To investigate the mechanism behind the action of RIP-140, the expression of 23
different metabolites involved in cellular respiration were monitored using RT-qPCR in
wild type and RIPKO immortalized MEF cells. GLUT3 expression was found to have
increased more than two-fold in RIPKO compared to the wild type control. Silencing
RIP-140 expression resulted in doubling the GLUT3 expression in the breast cancer cell
lines MCF7 and MDA-MB-436. Moreover, analyzing the RNAseq data obtained from 1068
breast tumor samples on the TCGA dataset showed that higher RIP140 expression resulted
in 20% higher probability to survive for 60 months. Having demonstrated the correlation
between RIP140 levels and GLUT3 expression, the authors proposed that GLUT3 can be
used as a prognostic tool that can help oncologists identify patients with low RIP140 levels
who would benefit the most from treatments that target glycolysis [83].
3.2.2. Colon Cancer
With no effective therapeutics in place, colon cancer is one of the leading causes of
death in cancer patients worldwide. One study found that GLUT5 mRNA levels in colon
cancer specimens from 30 different patients were double those of normal colon epithelial
cells. It was also found that treating the cancer cell line HT-29 with the GLUT5 inhibitor
MSNBA caused a 50% drop in cell viability at just 1 µM of inhibitor. Higher concentrations
showed diminishing returns and also started to affect the viability of normal cells [84].
A more recent study helped uncover the role that GLUT5 plays in colon cancer
proliferation and resistance to chemotherapy. GLUT5 is a fructose only transporter, and
uptake studies with HCT116 and HT29 cancer cell lines showed that when glucose is
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a dose of 2.5 ng/mL caused the biggest spike in GLUT6 expression by nearly 20-fold, and
bigger dose like 20 ng/mL only caused a nine-fold increase. In addition, TNFα treatment
a bigger dose like 20 ng/mL only caused a nine-fold increase. In addition, TNFα treatment
caused the phosphorylation of RELA at Ser536, which suggests the activation of the NF-κB
caused the phosphorylation of RELA at Ser536, which suggests the activation of the NFsignaling pathway. The authors concluded that the NF-κB signaling pathway plays an
κB signaling pathway. The authors concluded that the NF-κB signaling pathway plays an
important role in GLUT6 expression, providing further rationale to investigate and develop
important role in GLUT6 expression, providing further rationale to investigate and detherapeutics that target GLUT6 to treat this type of cancer [86].
velop therapeutics that target GLUT6 to treat this type of cancer [86].
3.2.4. Gastric Cancer
Several natural product extracts are known to inhibit the growth of this cancer, like
GRg3, which is found in ginseng, but their mechanism of action remains unknown. GRg3
was shown in previous studies to have antioxidant and anti-inflammatory properties, as
well as inhibiting tumor metastasis and increasing the expression of pro-apoptotic factors,
making it an attractive candidate to study further. The effect of GRg3 on GLUT expression
in normal gastric mucosa cells and gastric precancerous lesion cells were measured. This
experiment was done for GLUTs 1, 3, 4, 6, 10, and 12. Only GLUT1 and GLUT4 were found
to be overexpressed in the malignant cells compared to the healthy cells by 2.4-fold and
6-fold, respectively. Malignant cells treated with GRg3 had very close GLUT1 expression
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to the healthy cells, while GLUT4 expression remained higher than the healthy cells at
nearly two-fold, although it was four-fold lower than malignant cells with no treatment. To
further corroborate this evidence, the cancer cell lines AGS and HGC-27 were treated with
GRg3 and their GLUT expression was measured. The GLUT1 expression of AGS was half
of the negative control, and GLUT4 expression was lower by about 40%. HGC-27 cells had
nearly identical results, with GLUT1 expression being halved and GLUT4 expression being
40% lower. The expression of the other 4 GLUTs that were measured remained largely
unchanged. The authors concluded that GRg3 is not only a potentially effective therapeutic
for gastric cancer, but might also halt and reverse the development of precancerous lesions,
which could help reduce the incidence of this type of cancer [87].
Along a similar vein, the combination of Coptis chinensis (CC) and dried ginger (DG) is
used in traditional Chinese medicine to treat colds, gastric ulcers, and colitis. To understand
the mechanism behind the properties of CC-DG, the human gastric cell line SGC7901 was
treated with several CC-DG extracts in different proportions, and it was found that a 1:1
CC-DG ratio provided the maximum inhibition. Treatments with more CC came very
close to the results of the 1:1 ratio, with 24:1 having 90% of the inhibitory effect of the
1:1 treatment. Treatments with more DG, on the other hand, lost their effectiveness very
rapidly, with the 1:3 ratio having just 60% of the 1:1 inhibitory effect. Next, a cell viability
assay using this 1:1 CC-DG ratio was carried out on SGC7901 cells and also the mouse
gastric carcinoma cell line MFC. Both cell lines exhibited a significant reduction in viability
after 24 h in a linear dose-dependent manner. At the maximum dose of 2000 µg/mL, both
cell lines had a viability of about 40% and 37%, respectively. Following this, the impact of
CC-DG on cellular metabolites was tested, and it was found that it significantly reduces
GLUT1 and LDHA expression by 55% and 50% respectively in SGC7901 cells. Finally, MFC
cells were transplanted in mice and given different doses of the CC-DG treatment over
22 days. The mice given the 50 mg/kg dose had nearly 40% lower tumor volume and half
the tumor weight, while the mice given 100 mg/kg dose had 66% lower tumor volume and
87% lower weight. The authors concluded that the CC-DG medicine has potent anti-tumor
effects that target glucose metabolism and thus may prevent or suppress gastric cancer [88].
3.2.5. Leukemia
H22954, a novel non-coding RNA, was previously shown by the authors to inhibit
the growth and induce apoptosis in leukemia cells. To further understand the underlying
mechanisms, an F-FDG uptake assay was carried out on K562 cells with or without H22954.
It was found that the treated cells had a 5% lower uptake than the untreated control.
To identify which transporter was affected by H22954, the gene expression profile of
stable K562 cells were compared with and without overexpressed H22954. Only GLUT10
expression was found to have decreased more than two-fold, while the rest of the GLUT
transporters were mostly unaffected. Next, the cells were given actinomycin D to prevent
the synthesis of new RNA, then the levels of GLUT10 were measured with and without
H22954 treatment. After 30 min, less than 50% of the initial GLUT10 RNA remained. This
suggests that H22954 reduces GLUT10 expression by accelerating the degradation of its
RNA. Finally, blocking the H22954 and GLUT10 RNA interaction sites resulted in fully
restored GLUT10 levels. In conclusion, H22954 has been shown to be a GLUT10 specific
target that could help develop future leukemia treatments [89].
3.2.6. Multiple Cancer GLUT Inhibitor
KL-11743 is a newly identified broad spectrum class I GLUT inhibitor (Figure 2). It
is orally bioavailable and well tolerated for doses up to 100 mg/kg/day with no death or
adverse effects. Treating the fibrosarcoma cell line HT-1080 with this inhibitor showed a
potent dose-dependent growth inhibition (IC50 = 677 nM). Moreover, the cellular consumption of glutamine increased with the dose of inhibitor, going up by 40% at 3 µM of inhibitor.
This suggests that the cells are using glutamine as an alternative fuel source.
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Table 2. APOE4 associated odds ratios of developing MCI and dementia for different genotypes of
transporter genes.
Gene
Symbol
SLC2A1
(GLUT1)

SNP ID
rs710218
rs841851

SLC24A2
(SVCT)

rs1279683

Genotype
Group

APOE4
Odds Ratio

95% CI

p Value

TT
TA + AA
AA
AG + GG
GG
GA + AA

2.35
1.3
3.2
0.67
1.21
2.02

1.05–5.23
0.62–2.75
1.58–6.46
0.27–1.67
0.44–3.37
1.05–3.87

0.037
0.49
0.0012
0.39
0.71
0.035

3.4. Chron’s Disease
The increased presence of fructose in modern Western diets is suspected to have
played a role in the increasing prevalence of inflammatory bowel diseases. A recent study
provided evidence to support that hypothesis by feeding a 15 kcal% fructose diet to two
groups of mice with different GLUT5 expression levels. It was found that the mice with
lower GLUT5 levels experienced worse experimental colitis. Subsequent treatment of
those mice with broad spectrum antibiotics protected against worsening symptoms. Those
findings indicate that lower GLUT5 expression and dietary fructose intake both increase
the risk of experimental colitis by affecting the gut microbiota composition [92].
3.5. Epilepsy
More than 50 million people worldwide suffer from epilepsy, and 50% of all epilepsies
in humans were found to have a genetic underlying cause. Most commonly, mutations in
ion channels including sodium, potassium, calcium, and chloride channels were associated
with epilepsy, with the potassium channel in particular being the most commonly associated
type. On the other hand, mutations in GLUT1 that lower its function were found in 12% of
patients with early-onset absence epilepsy [93]. GLUT1 deficiency syndrome has also been
linked with epilepsy, along with other disorders like microcephaly and developmental
delay. A ketogenic diet has been found to be an effective treatment for GLUT1 deficiency
and was recommended as a first line treatment for this disorder [94].
3.6. Hepatic Steatosis
Nearly a quarter of the world population suffers from non-alcoholic fatty liver disease,
and its increased incidence is being blamed on the higher consumption of fructose in
modern western diets. TM4SF5 is a is a membrane glycoprotein that is known to be
involved in several forms of steatosis resulting from a high-fat diet or a methionine-choline
deficient diet. However, its role in steatosis involving a high fructose diet is unknown.
It was previously shown that TM4SF5 knockout mice on a high sucrose diet had lower
hepatic accumulation of triacylglycerols compared to wild type mice on the same diet. It
was also found that GLUT8 changes its intracellular location depending on the presence
of TM4SF5. To investigate this further, HepG2 cells were transfected with either GLUT2
or GLUT8 and with or without TM4SF5 silencing RNA. The cells were starved of glucose
for 16 h and then given 450 mg/dL fructose before being lysed for western blot analysis.
It was found that the cells with silenced TM4SF5 overexpressed GLUT8 but not GLUT2.
Moreover, the presence of lipogenic enzymes that are dependent on TM4SF5 was visibly
reduced when GLUT8 was silenced. Those findings suggest that the steatosis pathways
that are triggered by high fructose intake are reliant on GLUT8 as the primary fructose
transporter in hepatic cells. Targeting GLUT8 or TM4SF5 are promising approaches that
have the potential to block the development of non-alcoholic fatty liver disease [95].
3.7. Osteonecrosis
Steroid-induced osteonecrosis of the femoral head (SONFH) is a chronic and crippling
bone disease which is not yet fully understood despite being fairly common, with nearly

Int. J. Mol. Sci. 2022, 23, 8698

10 of 15

15,000 new reported cases annually in the United States alone. The diagnostic criteria of
this disease are fairly well established. However, due to the lack of specific symptoms
or biomarkers at the early stages, the majority of patients are diagnosed at the advanced
stages, where they will often require total hip replacement surgery. In order to identify new
biomarkers that could help in earlier detection of this disease, the authors screened the
GSE123568 dataset for differentially expressed genes and identified the module that had
the strongest correlation with SONFH (p = 7.1 × 10−278 ). Further analysis narrowed that
module down to four genes, RHAG, RNF14, HEMGN and SLC2A. Those genes had lower
expression in the SONFH group by 33%, 21%, 40% and 30%, respectively. Finally, the ROC
curves for those genes showed that all of them were above 0.9, indicating that they could
serve as potential diagnostic biomarkers for SONFH.
RHAG is a member of the transporter family SLC42 and is involved in ammonia transport. RNF14 is a prostate coactivator that is involved in the androgen receptor signaling
pathway. There have been no studies indicating that those proteins are involved in the development and progression of SONFH. On the other hand, HEMGN is expressed and bone
marrow and osteoblasts and is involved in osteoblast recruitment, which means it is likely
to be involved in the development of the disease. Finally, SLC2A1 is the sugar transporter
GLUT1, and it has been shown in the past that blocking it results in impaired osteoblast
anabolic function, differentiation, and mineralization in vitro. The authors concluded that
HEMGN and SLC2A1 are the most likely to serve as useful early diagnostic biomarkers of
SONFH, and additional experimental validation is needed [96].
3.8. Type 2 Diabetes
Trilobatin, a natural food additive found in Lithocarpus polystachyus leaves, was shown
to significantly reduce high fasting blood glucose levels and insulin resistance in diabetic
mice. Examining the mechanism of action revealed that trilobatin activated the Nrf2/ARE
signaling pathway that reduces oxidative stress and increased GLUT2 expression by an
average of 20% and 25% in the pancreas and liver, respectively, which lowered blood
glucose levels and improved insulin sensitivity [97]. A similar effect was observed with
the known antihyperglycemic molecule cyanidin-3-O-glucoside, which works on GLUT1
instead of GLUT2 [98].
Another study using a zebrafish model found that 1,25-dihydroxyvitamin D3 , the most
potent vitamin D metabolite, increased the expression of GLUT2 and the insulin receptor
insra. Those effects were observed only at a high glucose concentration of 20 mM, where
the GLUT2 expression was observed to have nearly doubled compared to the control. By
contrast, the low glucose concentration of 10 mM resulted in a very small increase in GLUT2
expression that was within the margin of error. In addition, treating diabetic zebrafish with
that vitamin D3 caused a significant reduction in visible hyperglycemia symptoms, which
are growth retardation and the body being curved rather than straight [99].
4. Summary and Conclusions
This review contains examples of GLUT involvement in a diverse set of disorders and
diseases from the recent literature. Most notably, the involvement of class III GLUTs in
those disorders, highlighted in Table 3, warrants further investigation into their structures
and roles, as currently the focus in research and available data mostly only focus on class I
and GLUT5 of class II.
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which seems to be a less popular area of research compared to GLUT inhibitors. There are
relatively fewer examples of GLUT activators and their therapeutic potential in the literature, and this might be a topic for a future review.
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